Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709443 | 0.83 | TP53 (0.43) | TSHRALDH1A1GLAKMT2AMEN1 | |
| SCHEMBL9622093 | 0.81 | ALDH1A1 (0.37) | TSHRALDH1A1GLAKMT2AMEN1 | |
| SCHEMBL2807180 | 0.80 | TSHR (0.41) | TSHRALDH1A1HTTMAPK1MAPT | |
| SCHEMBL489807 | 0.79 | TDP1 (0.44) | KMT2AMEN1TP53NPSR1ESR1 | |
| SCHEMBL6696457 | 0.78 | CHRM5 (0.43) | MAPTSLC6A2SMN1; SMN2 | |
| SCHEMBL4480480 | 0.78 | ESR1 (0.46) | TSHRALDH1A1KMT2AMEN1TP53 | |
| SCHEMBL14121955 | 0.78 | ALDH1A1 (0.37) | ALDH1A1KMT2AMEN1MAPK1MAPT | |
| SCHEMBL704306 | 0.78 | NPC1 (0.47) | KMT2AMEN1TP53NPSR1ESR1 | |
| SCHEMBL7668425 | 0.77 | NPSR1 (0.39) | TSHRALDH1A1GLAKMT2AMEN1 | |
| SCHEMBL27458991 | 0.77 | ALDH1A1 (0.34) | TSHRALDH1A1GLAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 686 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | claimed |
| US-9328099-B2 | Cyanomethylpyrazole carboxamides as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-03 | — | — | US | claimed |
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-08-14 | — | — | US | claimed |
| EP-1790639-B1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2014-03-26 | — | — | EP | claimed |
| US-7951816-B2 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | claimed |
| EP-1896467-B1 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-01 | — | — | EP | claimed |
| US-20100237770-A1 | GOLD COMPLEX AND PROCESS FOR PREPARING THE SAME, AND ORGANIC ULTRAVIOLET ELECTROLUMINESCENT DEVICE USING SAID GOLD COMPLEX | UBE INDUSTRIES, LTD. (JP) | 2010-09-23 | — | — | US | claimed |
| US-7582650-B2 | Tricyclic opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-01 | — | — | US | claimed |
| EP-2088151-A1 | GOLD COMPLEX, METHOD FOR PRODUCTION OF THE GOLD COMPLEX, AND ORGANIC ULTRAVIOLET ELECTROLUMINESCENT ELEMENT USING THE GOLD COMPLEX | Ube Industries, Ltd. (JP) | 2009-08-12 | — | — | EP | claimed |
| CN-101243079-A | Tricyclic opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-13 | — | — | CN | claimed |
| WO-1996003392-A1 | SUBSTITUTED THIAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | claimed |
| EP-0531883-A1 | Condensed 5-membered ring heterocycles, process for their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1993-03-17 | — | — | EP | claimed |
| US-5140009-A | Stable against proteolytic enzymes; anticarcinogenic agents; urogenital disorders | TAP PHARMACEUTICALS, INC. (US) | 1992-08-18 | — | — | US | claimed |
| EP-0480918-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1992-04-22 | — | — | EP | claimed |
| EP-0480918-A4 | REDUCED SIZE LHRH ANALOGS. | ABBOTT LAB (US) | 1991-06-04 | — | — | EP | claimed |
| EP-0417454-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1991-03-20 | — | — | EP | claimed |
| WO-1989007451-A1 | REDUCED SIZE LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328089-A2 | Reduced size LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
| EP-0019369-B1 | ISOTHIOUREIDO ISOINDOLEDIONES, PROCESS FOR THEIR PREPARATION AND USE AS PLANT REGULATORS | Gulf Oil Corporation (US) | 1984-03-07 | — | — | EP | claimed |
| US-3980430-A | CATIONIC DYE, HALOGENATED HYDROCARBON | BAYER AKTIENGESELLSCHAFT (DT) | 1976-09-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100237770-A1 | GOLD COMPLEX AND PROCESS FOR PREPARING THE SAME, AND ORGANIC ULTRAVIOLET ELECTROLUMINESCENT DEVICE USING SAID GOLD COMPLEX | APOL1, UFL1, ACSL3 | TSHR 2791/4885ALDH1A1 435/4885GLA 2095/4885 |
| US-20140228348-A1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | TSHR 1748/4885ALDH1A1 1995/4885GLA 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.